Assistant Professor of Medicine
Member of the Duke Cancer Institute
Campus mail
DUMC 103861, Durham, NC 27710
Phone
(919) 668-4667
Email address
tian.zhang2@duke.edu
Education and Training
- Fellowship in Hematology-Oncology, Medicine, Duke University School of Medicine, 2012 - 2015
- Internal Medicine Residency, Medicine, Duke University School of Medicine, 2009 - 2012
- M.D., Harvard Medical School, 2009
Grants
- Mirati 516-003
- A Phase III, Randomized, Double-Blind, Placebo-Controlled Clinical Trial of Pembrolizumab (MK-3475) as Monotherapy in the Adjuvant Treatment of Renal Cell Carcinoma Post Nephrectomy (KEYNOTE-564)
- A Salvage Trial of AR Inhibition with ADT and Apalutamide with Docetaxel followed by Radiation Therapy in Men with PSA Recurrent Prostate Cancer after Radical Prostatectomy (¿STARTAR¿)
- Merrimack MM-310-01-01-01
- An Open-Label Study of Rovalpituzumab
- A first in human study of repeat dosing with REGN2810 a fully human antibody to programmed death - 1 (PD-1) as single therapy and in combination with selected
- Phase II study of AGS-16C3F vs Axitinib in Metastatic Renal Cell Carcinoma
- Predicting patient-specific responses to personalize androgen deprivation therapy for prostate cancer
- Validation of Prostate Cancer Stem Cell Model in First and Second Line Hormone Therapy
- A Phase 1b, open label, prospective, non-randomized,single center study of conditional lethalithy to copper as a therapeutic modality in prostate cancer
- Conditional lethality of copper and disulfiram as a therapeutic modality for prostate cancer
- Duke-UNC-Wash U Partnership for Early Phase Clinical Trials in Cancer
- CTC-Immune Checkpoints
- A Phase I/II open label multicenter study of the safety and efficacy of LAG525 single agent in combination with PDR001 adminitered to patients
- A Retrospective Study to Evaluate the Clinical Effectiveness of the OmniSeq Immune Advance Test to Predict Response to Checkpoint Inhibitors